Exenatide results: what to expect and when

An older GLP-1 with twice-daily and weekly forms, now widely discontinued.

Also called: Byetta, Bydureon, Bydureon BCise, exendin-4, AC2993, ITCA 650.

GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.

334 registered interventional records found before the cutoff, including planned trials and comparator arms. Selected major reports appear below; this is not a completed-trial count.

Key studies

  • Early weight-based injections: Across active regimens, reductions ranged 0.7–1.1%; 15% reached HbA1c <7% versus 4% with placebo. (source)
  • Twice-daily dose finding: 2.5/5/7.5/10 mcg: −0.7/−0.7/−1.4/−1.8 kg; placebo 0.0 kg. (source)
  • AMIGO: added to a sulfonylurea: 10 mcg −0.86%; 5 mcg −0.46%; placebo +0.12%. (source)
  • AMIGO: added to metformin: 10 mcg −0.78%; 5 mcg −0.40%; placebo +0.08%. (source)
  • AMIGO: metformin plus sulfonylurea: 10 mcg −0.8%; 5 mcg −0.6%; placebo +0.2%. (source)
  • Weekly depot dose finding: 0.8 mg −1.4%; 2 mg −1.7%; placebo +0.4%. (source)

Related to Exenatide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.